Abstract
Overview
Introduction
Irritable bowel syndrome (IBS) is a common disease affecting 10-20% of the
total adult population, particularly women, in which recurrent abdominal pain
or discomfort is associated with defecation or changes in bowel habit. The
majority of sufferers have never consulted a physician about their symptoms
and remain undiagnosed.
Scope
*Quantification of the epidemiology and patient segmentation in IBS, including
a breakdown of the patient population by gender and symptom type *Discussion
of issues with regards to IBS patient presentation, referral patterns and
diagnosis such as the new Rome III diagnostic criteria *Overview of the
current treatment controversies and unmet needs, including the market
withdrawal of Novartis' Zelnorm (tegaserod) *Analysis of clinical trial design
the R&D drug pipeline for new IBS drug therapies in 2007
Report Highlights
Despite the substantial impact IBS can have on sufferers' well being, about
70-80% of sufferers have not been formerly diagnosed. Although many patients
will have seen a doctor or nurse for their symptoms, they remain undiagnosed
and may have visited a healthcare professional on several occasions before
being formally diagnosed with IBS
Physicians frequently do not recognize IBS as a ' distinct' disease. Continuing
physician education is needed to change this attitude and improve diagnosis,
particularly in the primary care setting. A simple and easily accessible
diagnostic tool adapted specifically for non-specialists and clear peer
reviewed treatment guidelines are needed
The pipeline can be described as relatively innovative. The serotinergic class
accounts for a third of candidates, however, the poor safety record and market
withdrawal of Lotronex (alosetron) and Zelnorm has cast doubts over the
potential of this class. FDA non-approval of cilansetron is another setback
for the serotinergics
Reasons to Purchase
- *Quantify the key target segments of the IBS patient population across the
seven major markets
- *Gain insight into opinion leaders' thoughts on the major opportunities
and challenges facing the IBS market
- *Learn about key late-stage pipeline drugs and issues surrounding
diagnosis and clinical trial design
| 
View Cart
